Futura Medical (FUM LN) H1 results: Eroxon® trial plan amended; licensing discussions underway | Goals Soccer Centres (GOAL LN) Further downgrades overshadow various strategic positives | Murgitroyd Group (MUR LN) Trading in line after record H2 performance | Oxford Instruments (OXIG LN) FY18 guidance maintained, but dependent on stronger H2 | Summit Therapeutics (SUMM LN) BARDA contract a major boost to ridinilazole | Vernalis (VER LN) Solid FY results driven by NCE collaborations; Tuzistra bro ....
12 Sep 2017
N+1 Singer - Morning Song 12-09-2017
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Morning Song 12-09-2017
Oxford Instruments plc (OXIG:LON), 2,058 | Goals Soccer Centres (GOAL:LON), 0 | Murgitroyd Group (MUR:LON), 0 | Futura Medical plc (FUM:LON), 39.4 | Summit Therapeutics Inc (SMMT:NAS), 0 | VERBUND AG Class A (0NR1:LON), 0
- Published:
12 Sep 2017 -
Author:
Tintin Stormont -
Pages:
15
Futura Medical (FUM LN) H1 results: Eroxon® trial plan amended; licensing discussions underway | Goals Soccer Centres (GOAL LN) Further downgrades overshadow various strategic positives | Murgitroyd Group (MUR LN) Trading in line after record H2 performance | Oxford Instruments (OXIG LN) FY18 guidance maintained, but dependent on stronger H2 | Summit Therapeutics (SUMM LN) BARDA contract a major boost to ridinilazole | Vernalis (VER LN) Solid FY results driven by NCE collaborations; Tuzistra bro ....